Search

Your search keyword '"Cremolini, C"' showing total 762 results
Start Over Author "Cremolini, C"
762 results on '"Cremolini, C"'

1. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

Author

Karapetis, C. S., Liu, H., Sorich, M. J., Pederson, L. D., Van Cutsem, E., Maughan, T., Douillard, J. Y., O’Callaghan, C. J., Jonker, D., Bokemeyer, C., Sobrero, A., Cremolini, C., Chibaudel, B., Zalcberg, J., Adams, R., Buyse, M., Peeters, M., Yoshino, T., de Gramont, A., and Shi, Q.

Published
2024
Full Text
View/download PDF

3. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Author

Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., Cercek, A., Segal, N.H., Saltz, L., Varghese, A.M., Yaeger, R., Nusrat, M., Goldberg, Z., Ku, G.Y., El Dika, I., Margalit, O., Grinshpun, A., Kasi, P.M., Schilsky, R., Lutfi, A., Shacham-Shmueli, E., Khan Afghan, M., Weiss, L., Westphalen, C.B., Conca, V., Decker, B., Randon, G., Elez, E., Fakih, M., Schrock, A.B., Cremolini, C., Jayachandran, P., Overman, M.J., Lonardi, S., and Pietrantonio, F.

Published
2024
Full Text
View/download PDF

5. Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

Author

Germani, M.M., Vetere, G., Santamaria, F., Intini, R., Ghelardi, F., Bensi, M., Boccaccino, A., Minelli, A., Carullo, M., Ciracì, P., Passardi, A., Santucci, S., Giampieri, R., Persano, M., Fenocchio, E., Puccini, A., Lonardi, S., Pietrantonio, F., Salvatore, L., and Cremolini, C.

Published
2024
Full Text
View/download PDF

6. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience

Author

Moretto, R., Germani, M.M., Borelli, B., Conca, V., Rossini, D., Boraschi, P., Donati, F., Urbani, L., Lonardi, S., Bergamo, F., Cerma, K., Ramondo, G., D’Amico, F.E., Salvatore, L., Valente, G., Barbaro, B., Giuliante, F., Di Maio, M., Masi, G., and Cremolini, C.

Published
2024
Full Text
View/download PDF

7. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study

Author

Mazzoli, G., Nichetti, F., Shitara, K., Cohen, R., Lonardi, S., Cremolini, C., Elez, M.E., Chao, J., Fakih, M., Klempner, S.J., Jayachandran, P., Maron, S., Cowzer, D., Fornaro, L., Salvatore, L., Zhu, V., Aoki, Y., Cerantola, R., Bergamo, F., Salati, M., Ambrosini, M., Sabella, G., Randon, G., Overman, M.J., André, T., and Pietrantonio, F.

Published
2024
Full Text
View/download PDF

10. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Author

Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., and Santini, D.

Published
2022
Full Text
View/download PDF

12. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

Author

Tabernero, Josep, Argilés, Guillem, Falcone, Alfredo, Ciardiello, Fortunato, Goldberg, Richard, Bennouna, Jaafar, Argilés, Tabernero, J., Mulet, N., Limón, M.L., Valladares, M., Jiménez, P., Vieitez, J. M<ce:sup loc='post">a</ce:sup>, Grávalos, C., García-Alfonso, P., Santos, C., Páez, D., Tobeña, M., Sastre, J., García Paredes, B., Benavides, M., Aranda, E., Cano, M.T., Loupakis, F., Rguez Garrote, M., Guillén, C., Rivera, Ma F., Safont, J., Hiret, S., Bennouna, J., Pannier, D., Malka, D., Falcone, A., Cremolini, C., Mulet, Nuria, Valladares-Ayerbes, Manuel, Viéitez, José M., Grávalos, Cristina, García-Alfonso, Pilar, Santos, Cristina, Tobeña, María, García-Paredes, Beatriz, Benavides, Manuel, Cano, María T., Loupakis, Fotios, Rodríguez-Garrote, Mercedes, Rivera, Fernando, Goldberg, Richard M., Cremolini, Chiara, Tabernero, Josep M., and Aranda, Enrique

Published
2022
Full Text
View/download PDF

13. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Author

Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., and Cremolini, C.

Published
2022
Full Text
View/download PDF

14. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Author

Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., Marmorino, F., Zaniboni, A., Buonadonna, A., Masi, G., Lonardi, S., Pietrantonio, F., Falcone, A., Antonuzzo, A., and Cremolini, C.

Published
2021
Full Text
View/download PDF

15. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study

Author

Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., Santini, D., Zucchelli, G., Pella, N., Maiello, E., Passardi, A., Zaniboni, A., Ugolini, C., Fontanini, G., Falcone, A., Nyamundanda, G., Sadanandam, A., and Cremolini, C.

Published
2021
Full Text
View/download PDF

16. 7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis

Author

Raeisi, M., primary, Cohen, R., additional, Chibaudel, B., additional, Hurwitz, H., additional, Saltz, L., additional, Kabbinavar, F., additional, Tebbutt, N., additional, Maughan, T., additional, Douillard, J-Y., additional, Van Cutsem, E., additional, Bokemeyer, C., additional, Adams, R.A., additional, Zalcberg, J.R., additional, Yoshino, T., additional, Cremolini, C., additional, Shi, Q., additional, André, T., additional, and De Gramont, A., additional

Published
2024
Full Text
View/download PDF

17. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Author

Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

18. Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial)

Author

Coccolini, F, Mazzoni, A, Cremonini, C, Cobuccio, L, Pucciarelli, M, Vetere, G, Borelli, B, Strambi, S, Musetti, S, Miccoli, M, Cremolini, C, Salvetti, F, Fugazzola, P, Ceresoli, M, Elisa, N, Litvin, A, Lostoridis, E, Ahmed, A, Manatakis, D, Negoi, I, Ioannidis, O, Uzunoglu, M, Tochie, J, Cillara, N, Tomadze, G, Bala, M, Isik, A, Fonseca, V, Bellanova, G, Ghannam, W, Yalkin, O, Garcia, F, Altintoprak, F, Hadzhiev, D, Chirica, M, Zese, M, Balalis, D, Cui, Y, Luppi, D, Romeo, L, Muratore, A, Lunghi, E, Yovtchev, Y, Nikolopoulos, I, Omerovic, M, Zizzo, M, Ugoletti, L, Costa, G, Scalzone, R, Perrone, S, Occhionorelli, S, Nardi, M, Gubbiotti, F, Catena, F, Muhtaroglu, A, Scaramuzzo, R, Corte, H, Yanez, C, Zakaria, A, Seretis, C, Gelmini, R, Pappalardo, V, Paratore, F, Sydorchuk, R, Mulita, F, Kara, Y, Toma, E, Vailas, M, Sotiropoulou, M, Benedetti, F, Elbahnasawy, M, Sibilla, M, Martines, G, Goksoy, B, Parini, D, Zaghi, C, Podda, M, Osipov, A, Brisinda, G, Gambino, G, Akhmeteli, L, Doklestic, K, Loncar, Z, Micic, D, Lesevic, I, D'Agostino, F, Garzali, I, Caicedo, Y, Marcela, L, Marin, P, Perivoliotis, K, Ntentas, I, Kuptsov, A, Dimitrov, E, Chowdhury, S, Patel, T, Sartelli, M, Tartaglia, D, Chiarugi, M, Coccolini F., Mazzoni A., Cremonini C., Cobuccio L., Pucciarelli M., Vetere G., Borelli B., Strambi S., Musetti S., Miccoli M., Cremolini C., Salvetti F., Fugazzola P., Ceresoli M., Elisa N. G., Litvin A., Lostoridis E., Ahmed A. Y. Y. M., Manatakis D., Negoi I., Ioannidis O., Uzunoglu M. Y., Tochie J. N., Cillara N., Tomadze G., Bala M., Isik A., Fonseca V. C., Bellanova G., Ghannam W., Yalkin O., Garcia F. H., Altintoprak F., Hadzhiev D., Chirica M., Zese M., Balalis D., Cui Y., Luppi D., Romeo L., Muratore A., Lunghi E. G., Yovtchev Y., Nikolopoulos I., Omerovic M., Zizzo M., Ugoletti L., Costa G., Scalzone R., Perrone S., Occhionorelli S., Nardi M., Gubbiotti F., Catena F., Muhtaroglu A., Scaramuzzo R., Corte H., Yanez C., Zakaria A. D., Seretis C., Gelmini R., Pappalardo V., Paratore F., Sydorchuk R., Mulita F., Kara Y., Toma E. A., Vailas M., Sotiropoulou M., Benedetti F., Elbahnasawy M., Sibilla M. G., Martines G., Goksoy B., Parini D., Zaghi C., Podda M., Osipov A., Brisinda G., Gambino G., Akhmeteli L., Doklestic K., Loncar Z., Micic D., Lesevic I., D'Agostino F., Garzali I. U., Caicedo Y., Marcela L., Marin P. A. G., Perivoliotis K., Ntentas I., Kuptsov A., Dimitrov E., Chowdhury S., Patel T., Sartelli M., Tartaglia D., Chiarugi M., Coccolini, F, Mazzoni, A, Cremonini, C, Cobuccio, L, Pucciarelli, M, Vetere, G, Borelli, B, Strambi, S, Musetti, S, Miccoli, M, Cremolini, C, Salvetti, F, Fugazzola, P, Ceresoli, M, Elisa, N, Litvin, A, Lostoridis, E, Ahmed, A, Manatakis, D, Negoi, I, Ioannidis, O, Uzunoglu, M, Tochie, J, Cillara, N, Tomadze, G, Bala, M, Isik, A, Fonseca, V, Bellanova, G, Ghannam, W, Yalkin, O, Garcia, F, Altintoprak, F, Hadzhiev, D, Chirica, M, Zese, M, Balalis, D, Cui, Y, Luppi, D, Romeo, L, Muratore, A, Lunghi, E, Yovtchev, Y, Nikolopoulos, I, Omerovic, M, Zizzo, M, Ugoletti, L, Costa, G, Scalzone, R, Perrone, S, Occhionorelli, S, Nardi, M, Gubbiotti, F, Catena, F, Muhtaroglu, A, Scaramuzzo, R, Corte, H, Yanez, C, Zakaria, A, Seretis, C, Gelmini, R, Pappalardo, V, Paratore, F, Sydorchuk, R, Mulita, F, Kara, Y, Toma, E, Vailas, M, Sotiropoulou, M, Benedetti, F, Elbahnasawy, M, Sibilla, M, Martines, G, Goksoy, B, Parini, D, Zaghi, C, Podda, M, Osipov, A, Brisinda, G, Gambino, G, Akhmeteli, L, Doklestic, K, Loncar, Z, Micic, D, Lesevic, I, D'Agostino, F, Garzali, I, Caicedo, Y, Marcela, L, Marin, P, Perivoliotis, K, Ntentas, I, Kuptsov, A, Dimitrov, E, Chowdhury, S, Patel, T, Sartelli, M, Tartaglia, D, Chiarugi, M, Coccolini F., Mazzoni A., Cremonini C., Cobuccio L., Pucciarelli M., Vetere G., Borelli B., Strambi S., Musetti S., Miccoli M., Cremolini C., Salvetti F., Fugazzola P., Ceresoli M., Elisa N. G., Litvin A., Lostoridis E., Ahmed A. Y. Y. M., Manatakis D., Negoi I., Ioannidis O., Uzunoglu M. Y., Tochie J. N., Cillara N., Tomadze G., Bala M., Isik A., Fonseca V. C., Bellanova G., Ghannam W., Yalkin O., Garcia F. H., Altintoprak F., Hadzhiev D., Chirica M., Zese M., Balalis D., Cui Y., Luppi D., Romeo L., Muratore A., Lunghi E. G., Yovtchev Y., Nikolopoulos I., Omerovic M., Zizzo M., Ugoletti L., Costa G., Scalzone R., Perrone S., Occhionorelli S., Nardi M., Gubbiotti F., Catena F., Muhtaroglu A., Scaramuzzo R., Corte H., Yanez C., Zakaria A. D., Seretis C., Gelmini R., Pappalardo V., Paratore F., Sydorchuk R., Mulita F., Kara Y., Toma E. A., Vailas M., Sotiropoulou M., Benedetti F., Elbahnasawy M., Sibilla M. G., Martines G., Goksoy B., Parini D., Zaghi C., Podda M., Osipov A., Brisinda G., Gambino G., Akhmeteli L., Doklestic K., Loncar Z., Micic D., Lesevic I., D'Agostino F., Garzali I. U., Caicedo Y., Marcela L., Marin P. A. G., Perivoliotis K., Ntentas I., Kuptsov A., Dimitrov E., Chowdhury S., Patel T., Sartelli M., Tartaglia D., and Chiarugi M.

Abstract

Association of advanced age, neoplastic disease and immunocompromission (IC) may lead to surgical emergencies. Few data exist about this topic. Present study reports the preliminary data from the WIRES-T trial about patients managed for colorectal neoplastic emergencies in immunocompromised patients. The required data were taken from a prospective observational international register. The study was approved by the Ethical Committee with approval n. 17575; ClinicalTrials.gov Identifier: NCT03643718. 839 patients were collected; 753 (80.7%) with mild–moderate IC and 86 (10.3%) with severe. Median age was 71.9 years and 73 years, respectively, in the two groups. The causes of mild–moderate IC were reported such malignancy (753–100%), diabetes (103–13.7%), malnutrition (26–3.5%) and uremia (1–0.1%), while severe IC causes were steroids treatment (14–16.3%); neutropenia (7–8.1%), malignancy on chemotherapy (71–82.6%). Preoperative risk classification were reported as follow: mild–moderate: ASA 1–14 (1.9%); ASA 2–202 (26.8%); ASA 3–341 (45.3%); ASA 4–84 (11.2%); ASA 5–7 (0.9%); severe group: ASA 1-1 patient (1.2%); ASA 2–16 patients (18.6%); ASA 3–41 patients (47.7%); ASA 4–19 patients (22.1%); ASA 5–3 patients (3.5%); lastly, ASA score was unavailable for 105 cases (13.9%) in mild–moderate group and in 6 cases (6.9%) in severe group. All the patients enrolled underwent urgent/emergency surgery Damage control approach with open abdomen was adopted in 18 patients. Mortality was 5.1% and 12.8%, respectively, in mild–moderate and severe groups. Long-term survival data: in mild–moderate disease-free survival (median, IQR) is 28 (10–91) and in severe IC, it is 21 (10–94). Overall survival (median, IQR) is 44 (18–99) and 26 (20–90) in mild–moderate and severe, respectively; the same is for post-progression survival (median, IQR) 29 (16–81) and 28, respectively. Univariate and multivariate analyses showed as the only factor influencing mortality in mild–moderate and severe IC is

Published
2023

19. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

Author

Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., Raimondi, A., Nichetti, F., Martinetti, A., Battaglia, L., Perrone, F., Pruneri, G., Falcone, A., Di Bartolomeo, M., de Braud, F., Di Nicolantonio, F., Cremolini, C., and Pietrantonio, F.

Published
2018
Full Text
View/download PDF

20. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

Author

Cremolini, C., Antoniotti, C., Lonardi, S., Bergamo, F., Cortesi, E., Tomasello, G., Moretto, R., Ronzoni, M., Racca, P., Loupakis, F., Zaniboni, A., Tonini, G., Buonadonna, A., Marmorino, F., Allegrini, G., Granetto, C., Masi, G., Zagonel, V., Sensi, E., Fontanini, G., Boni, L., and Falcone, A.

Published
2018
Full Text
View/download PDF

21. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

Author

Pietrantonio, F., Di Nicolantonio, F., Schrock, A.B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P., Drilon, A., Hechtman, J.F., Christiansen, J., Gowen, K., Frampton, G.M., Gasparini, P., Rossini, D., Gigliotti, C., Kim, S.T., Prisciandaro, M., Hodgson, J., Zaniboni, A., Chiu, V.K., Milione, M., Patel, R., Miller, V., Bardelli, A., Novara, L., Wang, L., Pupa, S.M., Sozzi, G., Ross, J., Di Bartolomeo, M., Bertotti, A., Ali, S., Trusolino, L., Falcone, A., de Braud, F., and Cremolini, C.

Published
2018
Full Text
View/download PDF

22. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Author

Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

24. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

Author

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., Loupakis, F., Spada, D., Cinieri, S., Beretta, G., Falcone, A., de Braud, F., and Cremolini, C.

Published
2017
Full Text
View/download PDF

26. Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial)

Author

Coccolini F., Mazzoni A., Cremonini C., Cobuccio L., Pucciarelli M., Vetere G., Borelli B., Strambi S., Musetti S., Miccoli M., Cremolini C., Salvetti F., Fugazzola P., Ceresoli M., Elisa N. G., Litvin A., Lostoridis E., Ahmed A. Y. Y. M., Manatakis D., Negoi I., Ioannidis O., Uzunoglu M. Y., Tochie J. N., Cillara N., Tomadze G., Bala M., Isik A., Fonseca V. C., Bellanova G., Ghannam W., Yalkin O., Garcia F. H., Altintoprak F., Hadzhiev D., Chirica M., Zese M., Balalis D., Cui Y., Luppi D., Romeo L., Muratore A., Lunghi E. G., Yovtchev Y., Nikolopoulos I., Omerovic M., Zizzo M., Ugoletti L., Costa G., Scalzone R., Perrone S., Occhionorelli S., Nardi M., Gubbiotti F., Catena F., Muhtaroglu A., Scaramuzzo R., Corte H., Yanez C., Zakaria A. D., Seretis C., Gelmini R., Pappalardo V., Paratore F., Sydorchuk R., Mulita F., Kara Y., Toma E. A., Vailas M., Sotiropoulou M., Benedetti F., Elbahnasawy M., Sibilla M. G., Martines G., Goksoy B., Parini D., Zaghi C., Podda M., Osipov A., Brisinda G., Gambino G., Akhmeteli L., Doklestic K., Loncar Z., Micic D., Lesevic I., D'Agostino F., Garzali I. U., Caicedo Y., Marcela L., Marin P. A. G., Perivoliotis K., Ntentas I., Kuptsov A., Dimitrov E., Chowdhury S., Patel T., Sartelli M., Tartaglia D., Chiarugi M., Coccolini, F, Mazzoni, A, Cremonini, C, Cobuccio, L, Pucciarelli, M, Vetere, G, Borelli, B, Strambi, S, Musetti, S, Miccoli, M, Cremolini, C, Salvetti, F, Fugazzola, P, Ceresoli, M, Elisa, N, Litvin, A, Lostoridis, E, Ahmed, A, Manatakis, D, Negoi, I, Ioannidis, O, Uzunoglu, M, Tochie, J, Cillara, N, Tomadze, G, Bala, M, Isik, A, Fonseca, V, Bellanova, G, Ghannam, W, Yalkin, O, Garcia, F, Altintoprak, F, Hadzhiev, D, Chirica, M, Zese, M, Balalis, D, Cui, Y, Luppi, D, Romeo, L, Muratore, A, Lunghi, E, Yovtchev, Y, Nikolopoulos, I, Omerovic, M, Zizzo, M, Ugoletti, L, Costa, G, Scalzone, R, Perrone, S, Occhionorelli, S, Nardi, M, Gubbiotti, F, Catena, F, Muhtaroglu, A, Scaramuzzo, R, Corte, H, Yanez, C, Zakaria, A, Seretis, C, Gelmini, R, Pappalardo, V, Paratore, F, Sydorchuk, R, Mulita, F, Kara, Y, Toma, E, Vailas, M, Sotiropoulou, M, Benedetti, F, Elbahnasawy, M, Sibilla, M, Martines, G, Goksoy, B, Parini, D, Zaghi, C, Podda, M, Osipov, A, Brisinda, G, Gambino, G, Akhmeteli, L, Doklestic, K, Loncar, Z, Micic, D, Lesevic, I, D'Agostino, F, Garzali, I, Caicedo, Y, Marcela, L, Marin, P, Perivoliotis, K, Ntentas, I, Kuptsov, A, Dimitrov, E, Chowdhury, S, Patel, T, Sartelli, M, Tartaglia, D, and Chiarugi, M

Subjects
Survival, Colon, Emergency, Acute care, Surgery, Morbidity, Mortality, Immunosuppression, Cancer
Abstract

Association of advanced age, neoplastic disease and immunocompromission (IC) may lead to surgical emergencies. Few data exist about this topic. Present study reports the preliminary data from the WIRES-T trial about patients managed for colorectal neoplastic emergencies in immunocompromised patients. The required data were taken from a prospective observational international register. The study was approved by the Ethical Committee with approval n. 17575; ClinicalTrials.gov Identifier: NCT03643718. 839 patients were collected; 753 (80.7%) with mild–moderate IC and 86 (10.3%) with severe. Median age was 71.9 years and 73 years, respectively, in the two groups. The causes of mild–moderate IC were reported such malignancy (753–100%), diabetes (103–13.7%), malnutrition (26–3.5%) and uremia (1–0.1%), while severe IC causes were steroids treatment (14–16.3%); neutropenia (7–8.1%), malignancy on chemotherapy (71–82.6%). Preoperative risk classification were reported as follow: mild–moderate: ASA 1–14 (1.9%); ASA 2–202 (26.8%); ASA 3–341 (45.3%); ASA 4–84 (11.2%); ASA 5–7 (0.9%); severe group: ASA 1-1 patient (1.2%); ASA 2–16 patients (18.6%); ASA 3–41 patients (47.7%); ASA 4–19 patients (22.1%); ASA 5–3 patients (3.5%); lastly, ASA score was unavailable for 105 cases (13.9%) in mild–moderate group and in 6 cases (6.9%) in severe group. All the patients enrolled underwent urgent/emergency surgery Damage control approach with open abdomen was adopted in 18 patients. Mortality was 5.1% and 12.8%, respectively, in mild–moderate and severe groups. Long-term survival data: in mild–moderate disease-free survival (median, IQR) is 28 (10–91) and in severe IC, it is 21 (10–94). Overall survival (median, IQR) is 44 (18–99) and 26 (20–90) in mild–moderate and severe, respectively; the same is for post-progression survival (median, IQR) 29 (16–81) and 28, respectively. Univariate and multivariate analyses showed as the only factor influencing mortality in mild–moderate and severe IC is the ASA score. Colorectal neoplastic emergencies in immunocompromised patients are more frequent in elderly. Sigmoid and right colon are the most involved. Emergency surgery is at higher risk of complication and mortality; however, management in dedicated emergency surgery units is necessary to reduce disease burden and to optimize results by combining oncological and acute care principles. This approach may improve outcomes to obtain clinical advantages for patients like those observed in elective scenario. Lastly, damage control approach seems feasible and safe in selected patients.

Published
2023

27. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E, Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, and Martinelli, E

Subjects
metastatic colorectal cancer, cetuximab, rechallenge, immunotherapy
Abstract

The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti-EGFR based-therapy. We performed a pooled analysis of two-phase II prospective trials to determine the role of rechallenge in third-line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third-line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Stable disease (SD) > 6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0-4.9) with median OS (mOS) of 16.9 months (95% CI 11.7-22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7-6.2); mOS was 13.1 months (95% CI 7.3-18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0-5.2); mOS was 18.6 months (95% CI 11.7-25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third-line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

Published
2023

28. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

Author

Researchgr. Nucleaire Geneeskunde, Cancer, Epi Kanker Team B, Team Medisch, Circulatory Health, Punt, C J A, Heinemann, V, Maughan, T, Cremolini, C, Van Cutsem, E, McDermott, R, Bodoky, G, André, T, Osterlund, P, Teske, A J, Pfeiffer, P, Researchgr. Nucleaire Geneeskunde, Cancer, Epi Kanker Team B, Team Medisch, Circulatory Health, Punt, C J A, Heinemann, V, Maughan, T, Cremolini, C, Van Cutsem, E, McDermott, R, Bodoky, G, André, T, Osterlund, P, Teske, A J, and Pfeiffer, P

Published
2023

29. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G., primary, Ciardiello, D., additional, Famiglietti, V., additional, Rossini, D., additional, Antoniotti, C., additional, Troiani, T., additional, Napolitano, S., additional, Esposito, L., additional, Latiano, T. P., additional, Maiello, E., additional, Del Re, M., additional, Lonardi, S., additional, Aprile, G., additional, Santini, D., additional, Masi, G., additional, Avallone, A., additional, Normanno, N., additional, Pietrantonio, F., additional, Pinto, C., additional, Ciardiello, F., additional, Cremolini, C., additional, and Martinelli, E., additional

Published
2023
Full Text
View/download PDF

30. 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial

Author

Botticelli, A., primary, Scagnoli, S., additional, Conte, P.F., additional, Cremolini, C., additional, Ascierto, P.A., additional, Aglietta, M., additional, Mazzuca, F., additional, Capoluongo, E., additional, Malapelle, U., additional, Nuti, M., additional, D'Amati, G., additional, Cerbelli, B., additional, Pruneri, G., additional, Giannini, G., additional, Cappuzzo, F., additional, Biffoni, M., additional, Blandino, G., additional, Cognetti, F., additional, Curigliano, G., additional, and Marchetti, P., additional

Published
2023
Full Text
View/download PDF

31. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials

Author

Sunakawa, Y., Stintzing, S., Cao, S., Heinemann, V., Cremolini, C., Falcone, A., Yang, D., Zhang, W., Ning, Y., Stremitzer, S., Matsusaka, S., Yamauchi, S., Parekh, A., Okazaki, S., Berger, M.D., Graver, S., Mendez, A., Scherer, S.J., Loupakis, F., and Lenz, H.-J.

Published
2015
Full Text
View/download PDF

32. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Author

Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., Cortesi, E., Tomasello, G., Spadi, R., Zaniboni, A., Tonini, G., Barone, C., Vitello, S., Longarini, R., Bonetti, A., D'Amico, M., Di Donato, S., Granetto, C., Boni, L., and Falcone, A.

Published
2015
Full Text
View/download PDF

34. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

Author

Falvella, F S, Cremolini, C, Miceli, R, Nichetti, F, Cheli, S, Antoniotti, C, Infante, G, Martinetti, A, Marmorino, F, Sottotetti, E, Berenato, R, Caporale, M, Colombo, A, de Braud, F, Di Bartolomeo, M, Clementi, E, Loupakis, F, and Pietrantonio, F

Published
2017
Full Text
View/download PDF

39. 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial

Author

Botticelli, A., primary, Scagnoli, S., additional, Conte, P.F., additional, Cremolini, C., additional, Ascierto, P.A., additional, Cappuzzo, F., additional, Aglietta, M., additional, Mazzuca, F., additional, Capoluongo, E., additional, Blandino, G., additional, Malapelle, U., additional, Nuti, M., additional, D'Amati, G., additional, Cerbelli, B., additional, Pruneri, G., additional, Biffoni, M., additional, Giannini, G., additional, Cognetti, F., additional, Curigliano, G., additional, and Marchetti, P., additional

Published
2022
Full Text
View/download PDF

40. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies

Author

Fanotto, V., primary, Boccaccino, A., additional, Casagrande, M., additional, Bergamo, F., additional, Spagnoletti, A., additional, Santini, D., additional, Antoniotti, C., additional, Allegrini, G., additional, Daniel, F., additional, Nasca, V., additional, Rossini, D., additional, Zaniboni, A., additional, Borelli, B., additional, Carullo, M., additional, Conca, V., additional, Passardi, A., additional, Tamburini, E., additional, Masi, G., additional, Cremolini, C., additional, and Pella, N., additional

Published
2022
Full Text
View/download PDF

41. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

Author

Conca, V., primary, Germani, M.M., additional, Moretto, R., additional, Giordano, M., additional, Bergamo, F., additional, Prisciandaro, M., additional, Antoniotti, C., additional, Ugolini, C., additional, Santini, D., additional, Cupini, S., additional, Boccaccino, A., additional, Barsotti, G., additional, Pagani, F., additional, Niccoli, C., additional, Zaniboni, A., additional, Passardi, A., additional, Tamburini, E., additional, Latiano, T.P., additional, Fontanini, G., additional, and Cremolini, C., additional

Published
2022
Full Text
View/download PDF

42. 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study

Author

Germani, M.M., primary, Rossini, D., additional, Vetere, G., additional, Giordano, M., additional, Capone, I., additional, Manca, P., additional, Bergamo, F., additional, Conca, V., additional, Borelli, B., additional, Boccaccino, A., additional, Angelini, M., additional, Simionato, F., additional, Pella, N., additional, Morelli, C., additional, Zucchelli, G., additional, and Cremolini, C., additional

Published
2022
Full Text
View/download PDF

43. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Author

Fornaro, L., Lonardi, S., Masi, G., Loupakis, F., Bergamo, F., Salvatore, L., Cremolini, C., Schirripa, M., Vivaldi, C., Aprile, G., Zaniboni, A., Bracarda, S., Fontanini, G., Sensi, E., Lupi, C., Morvillo, M., Zagonel, V., and Falcone, A.

Published
2013
Full Text
View/download PDF

44. Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]

Author

Ros, J., Matito, J., Villacampa, G., Comas, R., Garcia, A., Martini, G., Baraibar, I., Saoudi, N., Salvà, F., Martin, Á., Antista, M., Toledo, R., Martinelli, E., Pietrantonio, F., Boccaccino, A., Cremolini, C., Dienstmann, R., Tabernero, J., Vivancos, A., and Elez, E.

Published
2024
Full Text
View/download PDF

49. 506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO

Author

Germani, M.M., Heinemann, V., Rossini, D., Fischer von Weikersthal, L., Morano, F., Heinrich, K., Stahler, A., Bergamo, F., Kaiser, F., Decker, T., Salvatore, L., Weiss, L., Russo, A., Fuchs, M., Prete, A.A., Antoniotti, C., Masi, G., Stintzing, S., Cremolini, C., and Modest, D.P.

Published
2024
Full Text
View/download PDF

50. 505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study

Author

Siena, S., Yamaguchi, K., Ruffinelli Rodriguez, J.C., Corral de la Fuente, E., Kuboki, Y., Cremolini, C., Victoria Ruiz, I., Elez Fernandez, M.E., Strickler, J.H., Furqan, M., Bashir, B., Nduka, C., Hippenmeyer, J., Chan, E., Xia, C., and Masuishi, T.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results